Tarsus Pharmaceuticals, Inc.
- TARS
- NASDAQ
- Biotechnology
- Ophthalmology Drugs
- Clinical-Stage Biopharma
$68.07
Today −4.11%Quote Oct 16, 2026, 08:00 PM UTC
−13.87%over the last month
Max drawdown −13.9%From 1-month high −13.9%3 months +21.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$3.19B
Quote Oct 16
Next earnings
Nov 3
Expected, not confirmed
Analyst target
$103.00
+51.3% from here
Floor
$66.43
2.4% below price
Where the price sits
10 analysts
Analyst range, low to high
$89.00$116.00
- Price $68.07
- Resistance $68.61
- Consensus $103.00
The price is right under resistance. Analysts' average target sits about 51% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TARSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
370